Tempus AI, Inc. Common Stock (TEM.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS
Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 14 advisor reports and comparisons.
Updated on 21 September 2026Deep analysis 21 September 2026
Russlan Ramdowar
Opus 5Universal Investor AI
The Polymath FrameworkModel rating
Neutral
5-Year Return Est.
+35.1%
TEM.NASDAQ does not currently pay dividends
Historical prices and published forecast
- Observed price
- Published advisor forecast
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning
Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.
| Quarter | Forecast | Total return | Scenario |
|---|---|---|---|
| $69.3 | -11.0% | Momentum unwinds as Q3 results in late October show roughly 22% growth against a guided second-half reacceleration. Consensus targets already sit below spot; a 5% 10-year compounds the de-rating of distant cash flows. | |
| $65.1 | -16.3% | Personalis closes and share issuance lands, diluting per-share metrics while first-year MRD losses consolidate. FY2027 guidance including the target disappoints on EBITDA, and January tax-loss rebound fades quickly. | |
| $70.3 | -9.6% | Unified ADLT pricing on tumor-only xT flows through Q1 reporting, adding near-full-margin revenue. Evidence of the promised free-cash-flow crossover restores confidence and draws growth capital back into profitable diagnostics names. | |
| $73.8 | -5.1% | General availability of the whole-genome research platform arrives mid-2027, converting an unpriced announcement into early licence bookings. Data and Applications outgrowing Diagnostics supports incremental multiple, offset by continued stock-compensation dilution. | |
| $78.3 | +0.6% | Full-year 2027 tracks toward the first positive free-cash-flow year. Easing inflation allows the Fed to pause, compressing term premium and mechanically lifting valuations of long-duration healthcare technology equities. | |
| $74.4 | -4.5% | Integration costs and Signatera price competition surface in Q4 reporting, capping MRD margin expectations. Guidance for 2028 growth near 18% underwhelms investors anchored to the acquisition-inflated growth narrative. | |
| $78.8 | +1.3% | Operating leverage becomes visible as gross margin approaches the high sixties and fixed bioinformatics costs spread across higher volumes. EBITDA margin crossing ten percent shifts the valuation debate from sales to earnings. | |
| $82.8 | +6.3% | Additional MolDX indication coverage for NeXT Personal broadens the reimbursable MRD market. Pharma data renewals demonstrate recurring revenue durability, lifting the quality of the revenue mix investors are paying for. | |
| $86.1 | +10.6% | Positive free cash flow for a full year removes financing overhang and dilution fears. However, decelerating headline growth near seventeen percent keeps the multiple anchored rather than expanding further. | |
| $88.7 | +13.9% | Steady execution with 2029 guidance in line. Convertible notes due 2032 begin entering refinancing discussion, a modest overhang balanced by accumulated cash and improved credit standing. | |
| $83.3 | +7.1% | A PAMA reimbursement rate review cycle reprices advanced diagnostic tests downward, trimming forward revenue estimates. Sector-wide multiple compression across molecular diagnostics amplifies the company-specific estimate cut. | |
| $88.3 | +13.5% | Management offsets rate pressure with volume growth and cost discipline, and the data segment's insensitivity to reimbursement becomes an explicit part of the equity story. Estimates stabilise and the stock recovers. | |
| $91.9 | +18.0% | Approaching three billion dollars of revenue with mid-teens EBITDA margin, the company screens as a profitable compounder rather than a speculative platform. Index and generalist ownership broadens the shareholder base. | |
| $94.6 | +21.6% | Full-year results confirm the margin trajectory. Growth settling near fifteen percent means returns now come from earnings accretion rather than re-rating, producing steady but unspectacular appreciation. | |
| $96.5 | +24.0% | Competitive intensity in MRD and comprehensive genomic profiling caps pricing. Incremental gains depend on algorithm monetisation finally converting the attach rate into billable revenue, a slow-moving reimbursement process. | |
| $91.7 | +17.8% | A broader risk-off episode in high-multiple healthcare technology, triggered by renewed rate volatility or a disappointing sector print, hits a still-elevated beta name harder than the index. | |
| $97.2 | +24.9% | Recovery as 2031 guidance shows EBITDA margin approaching twenty percent and genuine free-cash-flow yield emerges. Buyback capacity becomes plausible for the first time, changing the per-share arithmetic. | |
| $100 | +28.6% | Mature-platform valuation logic dominates: earnings growth plus modest share-count discipline drive returns. Convertible refinancing completes without meaningful dilution, removing a long-standing structural concern. | |
| $102 | +31.2% | Steady execution against a roughly four-billion-dollar revenue base. Upside now requires a new therapeutic-area or geographic expansion; absent that, the stock tracks earnings growth closely. | |
| $105 | +35.1% | Horizon close with the company established as a profitable precision-medicine platform. Cumulative five-year appreciation near forty percent reflects real earnings progress largely offset by the multiple compression from today's extended entry price. |
1. Investment Thesis — Base Case
The central tension is arithmetic, not narrative. Tempus has genuinely crossed from cash-burning data experiment to scaled diagnostics platform — Q2 2026 brought $382.5 million revenue, first GAAP net income and positive adjusted EBITDA — yet growth decelerated from 83% to 22% while the September re-rating to 9.9x sales already borrowed the 2027 margin bridge [1][7]. Base case: Personalis closes, ADLT pricing lifts 2027, EBITDA margin climbs toward the low twenties by 2030, but multiple compression consumes most of that fundamental progress. Investors collect mid-single-digit annualised returns along a violently uneven path.
- FY2026 guidance of $1.595-1.605 billion with ~$65 million adjusted EBITDA implies roughly 225x EV/EBITDA today.
- Assume $4.0 billion 2031 revenue at 22% EBITDA margin; 18x on ~215 million shares approximates $105.
- Cross-check: that $20 billion equity equals about 5x 2031 sales, still premium to mature diagnostics comparables.
2. Scenarios & Signals
2.1. Bull Case
The bull case activates when reimbursement and data monetisation arrive together rather than sequentially. Broadened MolDX coverage pushes NeXT Personal volumes through Tempus's existing hospital channel, MRD revenue quadruples, and the 100,000-genome library converts into nine-figure pharma licences at software margins. Consolidated growth reaccelerates above 25% with EBITDA margin near 30%, and the multiple expands rather than compresses because mix shifts toward recurring data revenue. The share price roughly doubles from here.
2.2. Bear Case
The bear case activates when decelerating growth meets a reimbursement cut. Q3 and Q4 2026 print near 20%, the guided second-half reacceleration fails, and analysts who chased targets above spot reverse hard. Personalis integration consumes management attention while Signatera defends share on price; a 2028 PAMA reset then erases the ADLT uplift. Goodwill exceeding tangible equity forces a write-down, and a 3.7-beta stock with no earnings floor retraces toward its $36 low.
2.3. Behavioral Alpha Signals
Sentiment, repricing cycle, crowd narrative, catalyst, and macro alignment.Expected Volatility Regime
Greed and Fear Index
Cycle Position
Price action and thesis reinforcement are feeding each other.
What does Media Tell? (Crowd Consensus)
The tape treats Tempus as the proven AI-in-healthcare winner: a first GAAP-profitable quarter, a transformational MRD acquisition and a 54% one-month gain have hardened into settled fact [1]. The anchoring bias is stark — consensus targets of $62-68 now sit below spot, meaning the crowd is pricing upgrades that have not yet been written, not fundamentals already delivered [19][20].
What Crowds Get Wrong? (Alpha/Value Gap)
The crowd overestimates these shares at $77.80 — modestly overpriced, not absurdly so. The overlooked evidence is arithmetic: market capitalisation roughly doubled from $7.48 billion in July to $14.2 billion in September without any change to FY2026 guidance [9]. That is pure multiple expansion borrowing the 2027 margin bridge in advance. The blind spot is the exchange-ratio reflexivity: the rally mechanically cheapens Personalis, which sell-side then cites as accretion, which justifies the rally. Circular logic, genuine business.
When will Value Gap Repricing Happen? (Repricing Catalyst)
Q3 2026 results, due late October, are the first clean read on whether the guided second-half reacceleration to roughly 24% is real or arithmetic. A print near 22% with unchanged guidance breaks the upgrade cycle. First observable sign: analysts trimming rather than chasing targets.
How is Asset Influenced by Macro Regime?
The macro wind is in its face. With the Fed at 3.75%-4.00%, another hike in the median dot and the 10-year near 5%, a pre-cash-flow name whose value sits in 2029-2031 carries maximum duration risk. Only a decisive disinflation turn — unlikely while Brent holds above $100 — reverses that transmission.
3. Positive & Negative Factors, Risks & Opportunities
3.1. Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Structural or operating forces that support this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Fixed COST BASE Finally Bends | Operational Efficiency | +22% | +48% | The operating margin moved from -99.7% in FY2024 to -19.88% in FY2025, and Q2 2026 produced $5.6 million of GAAP net income with $8.0 million adjusted EBITDA against $(42.8) million a year earlier [7]. Sequencing and bioinformatics costs are largely fixed; each incremental test and data query drops through. Management guides to adjusted EBITDA and free cash flow positive in 2027, which the evidence now supports. |
| ADLT Pricing Unlocks Tumor ONLY XT | Regulatory | +18% | +32% | FDA approval of tumor-only xT CDx permits unified Advanced Diagnostic Laboratory Test pricing, which management estimates adds roughly $85 million of annualised revenue from 2027 [8]. Because the incremental dollars land on tests already being run, flow-through to gross profit approaches full margin — the cleanest earnings lever in the model. It persists as long as CMS maintains ADLT status, reset annually against market rate. |
| DATA Flywheel Outgrows THE LAB | Innovation And Product | +15% | +22% | Data and Applications grew 28% in Q2 2026 versus 20% for Diagnostics, and the September initiative to assemble 100,000 linked whole genomes — targeting one million — extends the only genuinely defensible asset here [5][7]. Pharma pays recurring, high-margin licence fees for longitudinal multimodal data that cannot be replicated quickly. This mix shift raises blended gross margin and justifies a software-adjacent multiple component. |
| ZERO Coupon Money IN A 5% World | Capital Allocation | +8.0% | +10% | Tempus completed a $460 million 0.0% convertible senior notes offering due 2032, saving over $30 million of annual interest against comparable straight debt while the US 10-year sits near 5% [8]. Combined with $820.7 million of cash and marketable securities at June 2026, this removes near-term financing coercion and lets management fund Personalis integration without a distressed equity raise. The option cost is deferred dilution. |
Near-certain negative forces
Top Frictions / Headwinds
Expected frictions that can slow, cap, or damage this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Growth Decays While Multiple Stays | Competitive Positioning | -26% | -8.0% | Revenue growth fell from +83.4% in FY2025 — inflated by the Ambry acquisition — to +36.1% in Q1 2026 and +22% in Q2, with acquired hereditary cancer testing decelerating to 5% year-over-year [7][8]. At 9.9x TTM sales the security is priced for durable thirty-percent compounding. A Rule-of-40 score near 24 cannot support that multiple indefinitely; compression is the most probable single drag over five years. |
| FIVE Percent Discounts Distant CASH | Macroeconomic And Macrofinancial | -18% | +0.0% | The US 10-year closed at 4.998% on 18 September 2026 with the Fed at 3.75%-4.00% and the median dot implying another hike. Essentially all of Tempus's value sits in 2029-2031 cash flows; with a reported beta between 3.7 and 5.2, each 50 basis points of term premium removes a disproportionate slice of present value [1][2]. Persistent energy-driven inflation keeps this headwind engaged. |
| Stock Based Compensation AS Hidden TAX | Management And Governance | -15% | -12% | The first GAAP profit of $5.6 million sat alongside $54.1 million of quarterly stock-based compensation and negative $7.5 million operating cash flow [1][8]. TTM free cash flow remains -$273 million. Share count grows structurally, and the all-stock Personalis consideration adds roughly 17-28 million shares depending on the exchange ratio [10]. Per-share economics therefore improve far more slowly than headline EBITDA implies. |
| Signatera OWNS THE MRD Beachhead | Sector And Industry | -12% | -15% | Personalis brings four Medicare-covered indications and 1,400 ordering physicians, but Natera's Signatera is entrenched with far larger volumes, and Guardant and Exact Sciences are funding competing molecular residual disease assays [15]. Paying roughly 15x sales for a loss-making challenger invites a price war in a PAMA-governed reimbursement regime. Expect slower-than-modelled MRD revenue capture and first-year dilution to consolidated EBITDA. |
3.2. Risks & Opportunities
Plausible downside scenarios
Tail Risks
Less likely downside scenarios that could materially hurt the outcome if they occur.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| PAMA RATE Reset GUTS THE CORE | 28% | -42% | Advanced Diagnostic Laboratory Test status is repriced annually against reported market rates, and the broader Clinical Laboratory Fee Schedule faces repeated legislative deferral fights. A 2028-2029 reset that cuts xT or Ambry hereditary panel reimbursement by 15-20% would erase the entire $85 million ADLT uplift and push the 2027 free-cash-flow commitment out by years, collapsing the multiple on a business with no earnings cushion [8]. Probability sits below half because Congress has repeatedly delayed PAMA cuts. |
| Goodwill Meets Reality | 24% | -38% | Consolidated equity was $491 million at end-2025 against a price-to-book of 31.9; adding roughly $1.5 billion of Personalis purchase price on top of Ambry goodwill creates an impairment surface far larger than tangible net worth. If MRD volumes disappoint through 2028 and a non-cash write-down lands alongside a covenant or convertible-refinancing conversation, the equity story shifts from compounding platform to balance-sheet repair [10]. Below fifty percent because cash of $820.7 million buys considerable time. |
Plausible upside scenarios
Tail Opportunities
Less likely upside scenarios that could materially improve the outcome if they occur.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| MRD Reimbursement Breakout | 30% | +62% | If MolDX broadens coverage for NeXT Personal across additional solid tumours during 2027-2028 and Tempus channels the assay through its existing hospital connectivity and 45% algorithm attach base, MRD could scale from a ~$90 million run-rate toward $400 million at diagnostics-grade margins [9][14]. That would restore consolidated growth above 25% and re-rate the data segment alongside it. It stays below even odds because coverage decisions are indication-by-indication, Signatera holds the clinical-evidence lead, and PAMA rate resets cut the other way. |
| Pharma PAYS FOR THE Genome Library | 26% | +45% | The 100,000-genome initiative reaches general availability in mid-2027 [5][6]. A multi-year, nine-figure licensing framework with two or three large pharmaceutical sponsors — or an AI-model developer seeking clinically grounded training corpora — would convert an unpriced announcement into recurring, ~80% gross-margin revenue and justify a software multiple on a third of the business. Probability stays under half because the September announcement disclosed no contract value, and pharma R&D budgets face their own cost discipline through 2027-2028. |
5. References & Context
Search behavior, retained evidence, supplied context, and response token details.External web search was used. The retained search terms and consulted sources are shown below.
Context supplied to the model
Public-safe inputs retained with this immutable forecast publication.
- 01
Market data
inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
- 02
Global context in this run
Used
- 03
Fundamental data in this run
Used
- 04
Global context
Standard global market and cross-asset context
- 05
Subject context
Equity-specific subject and market context
- 06
Task framework
Standard investment-forecast task guidelines
- 07
Advisor framework
Universal Investor The Polymath
- 08
Forecast output requested
Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)
Global context snapshot
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2019-12-31–2025-12-31, 7 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Search terms retained
- 1.Tempus AI Q2 2026 results revenue guidance
- 2.Tempus AI TEM stock news September 2026
- 3.Tempus AI whole-genome dataset partnership September 11 2026
- 4.Tempus Personalis acquisition financing shares close Q4 2026 MRD Medicare reimbursement
- 5.Tempus AI 2027 revenue consensus estimate analyst price target short interest September 2026
Sources retained for this advisor
- [1]Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook - 24/7 Wall St.247wallst.com
- [2]Free Trialmarketbeat.com
- [3]Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum - StocksToTradestockstotrade.com
- [4]TEM Stock Quote Price and Forecast | CNNcnn.com
- [5]Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-driven Healthcare Innovationtempus.com
- [6]Tempus AI Building Multimodal Whole-Genome Dataset for AI Research | Bitget Newsbitget.com
- [7]Tempus AI posts Q2 profit on 22% revenue growth | TEM 8-K Filingstocktitan.net
- [8]Tempus AI Inc (TEM) (Q2 2026) Earnings Call Highlights: Revenue Surges 22% to $382. ...finance.yahoo.com
- [9]Earnings call transcript: Tempus AI beats Q2 2026 EPS view as stock trims gains By Investing.cominvesting.com
- [10]Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platformtempus.com
- [11]Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform | Tempus AIinvestors.tempus.com
- [12]Personalis, Inc. - Form 425 - FY2026sec.gov
- [13]Tempus AI (NasdaqGS:TEM) Stock Forecast & Analyst Predictions - Simply Wall Stsimplywall.st
- [14]Personalis, Inc. - Form 425 - FY2026sec.gov
- [15]Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliantfinance.yahoo.com
- [16]Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billionfinance.yahoo.com
- [17]Tempus AI Bets on MRD Testing Growth With Personalis Acquisitionfinance.yahoo.com
- [18]Tempus AI (TEM) Extends Rally After Earnings Beat And $1.5B Deal - StocksToTradestockstotrade.com
- [19]Tempus AI (TEM) Stock Price & Overviewstockanalysis.com
- [20]Tempus AI (TEM) Stock Forecast & Analyst Price Targetsstockanalysis.com
- [21]Tempus AI (Nasdaq:TEM) - Stock Analysis - Simply Wall Stsimplywall.st
- [22]Tempus AI (TEM) Rallies As Upgrade, Earnings And Personalis Deal Aligntimothysykes.com
Original published forecast
Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.
A consensus thesis is not available for this publication.